Ani Pharmaceuticals Inc's Revenue per employee fell on a trailing twelve month basis to $ 1,008,638, below the company average number of $307,976. Within the Healthcare sector Employees of 86 other companies have achieved higher revenue per employee. While Ani Pharmaceuticals Inc's total ranking has deteriorated compared to the previous quarter from 669 to 892. Ani Pharmaceuticals Inc has 970 employees.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has announced the successful launch of its generic Prucalopride Tablets, following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA). Prucalopride is the generic equivalent of the reference listed drug (RLD) Motegrity. This launch is notable not only for the introduction of a new treatment option for patients but also for the 180-day competitive market exclusivity granted by the FDA, which can enhance ANI’s market position in the gastrointestinal treatment space.Prucalopride is prescribed primarily for the treatment of chronic idiopathic constipation, providing a therapeutic alternative for patients unresponsive to traditional laxatives. This approval aligns with ANI Pharmaceuticals strategic initiatives to expand its portfolio of generic medications, which serves both to meet patient needs and to drive company growth.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
